Mucormycosis Treatment Market, By Species (Cunninghamella, Saksenaea, Rhizopus, Rhizomucor, Mucor, Lichtheimia, Apophysomyces And Others), By Diagnosis Method (Computed Tomography, Magnetic Resonance Imaging, Tissue Biopsy And Others.), By Treatment (Amphotericin B Therapy, Antifungal Medication, Surgery, And Others), By End-User, (Hospitals, Clinics, Research Organization, Medical Institute And Others) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Market for the treatment of mucormycosis was valued at US$ 399.7 million in 2020 and is projected to grow at a compound annual growth rate (CAGR) of 7.5% to reach US$ 822.0 million by 2030.

Despite treatment, mucormycosis is a highly treatable invasive fungal disease that poses a significant risk of morbidity and mortality. Mucormycosis in humans can present in a variety of ways, particularly in individuals with diabetes and immunocompromised conditions. The most common syndromes associated with these fungi are pulmonary infections and crippling rhino-orbital-cerebral infections. A class of molds known as mucormycetes is the source of the fungal infection mucormycosis. Fungal spores can also cause harm to the lungs and sinuses when inhaled, and the disease can enter the body through cuts, scrapes, burns, or other skin traumas. The prognosis for mucormycosis is typically not good. It depends on several elements, such as the patient's overall condition and capacity to respond to therapy, the rate at which A diagnosis is made and treatment is administered.